November 24, 2016 - By kentuckypostne · 0 Comments
The stock of Alliqua Biomedical DE (NASDAQ:ALQA) registered an increase of 9.87% in short interest. ALQA’s total short interest was 322,700 shares in November as published by FINRA. Its up 9.87% from 293,700 shares, reported previously. With 52,600 shares average volume, it will take short sellers 6 days to cover their ALQA’s short positions. The short interest to Alliqua Biomedical DE’s float is 1.56%. The stock decreased 0.16% or $0.001 on November 23, hitting $0.699. About 78,806 shares traded hands. Alliqua Biomedical Inc (NASDAQ:ALQA) has declined 1.41% since April 22, 2016 and is downtrending. It has underperformed by 6.82% the S&P500.
Alliqua BioMedical, Inc. is a provider of advanced wound care solutions. The company has a market cap of $19.47 million. The Company’s businesses include advanced wound care and contract manufacturing. It currently has negative earnings. The Firm operates through its subsidiaries, such as AquaMed Technologies, Inc. and Choice Therapeutics, Inc.
Insitutional Activity: The institutional sentiment decreased to 0.75 in Q2 2016. Its down 0.25, from 1 in 2016Q1. The ratio turned negative, as 4 funds sold all Alliqua Biomedical Inc shares owned while 7 reduced positions. 0 funds bought stakes while 11 increased positions. They now own 8.86 million shares or 14.99% less from 10.42 million shares in 2016Q1.
Ameriprise Fin Inc holds 0% or 50,000 shares in its portfolio. Perceptive Advisors Ltd last reported 1.92M shares in the company. The Germany-based Deutsche Financial Bank Ag has invested 0% in Alliqua Biomedical Inc (NASDAQ:ALQA). The Illinois-based Citadel Advsr Ltd Liability has invested 0% in Alliqua Biomedical Inc (NASDAQ:ALQA). National Bank & Trust Of America De holds 0% or 1,742 shares in its portfolio. Retail Bank Of Ny Mellon Corporation holds 0% of its portfolio in Alliqua Biomedical Inc (NASDAQ:ALQA) for 13,095 shares. Blackrock Fund holds 0% or 71,268 shares in its portfolio. Da Davidson And accumulated 0% or 9,500 shares. Us National Bank De has 181,732 shares for 0% of their US portfolio. Sabby Mgmt Limited Liability Corporation, a New Jersey-based fund reported 1.50 million shares. Wells Fargo & Mn reported 428 shares or 0% of all its holdings. Geode Capital Mngmt Ltd Liability Corporation owns 80,974 shares or 0% of their US portfolio. Ladenburg Thalmann Svcs Incorporated last reported 114 shares in the company. Savings Bank Of Montreal Can holds 0% or 3,500 shares in its portfolio. Welch Forbes Ltd Com reported 11,284 shares or 0% of all its holdings.
Out of 3 analysts covering Alliqua Biomedical (NASDAQ:ALQA), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Alliqua Biomedical has been the topic of 8 analyst reports since August 19, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating by RBC Capital Markets given on Wednesday, February 24. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, August 10. The stock has “Hold” rating given by Zacks on Wednesday, August 19. The firm has “Buy” rating given on Wednesday, February 24 by Chardan Capital Markets. The firm has “Buy” rating given on Friday, November 6 by Chardan Capital Markets. RBC Capital Markets maintained the shares of ALQA in a report on Friday, November 6 with “Outperform” rating. The firm has “Buy” rating given on Monday, November 2 by H.C. Wainwright.
Alliqua BioMedical, Inc., incorporated on April 15, 2014, is a well-known provider of wound care solutions. The Firm operates in commercial wound care segment, which consists of approximately five product categories, such as Wound Bed Preparation & Stimulation; Human Biologics; Antimicrobial Protection; Exudate Management, and Contract Manufacturing. The Firm has a suite of wound care solutions that enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds. The Firm has built its portfolio through its hydrogel technology platform, targeted acquisitions, and through licensing and distribution agreements. The Company’s contract manufacturing business provides custom hydrogels to the original equipment maker (OEM) market.
More notable recent Alliqua Biomedical Inc (NASDAQ:ALQA) news were published by: Globenewswire.com which released: “Alliqua BioMedical, Inc. Announces Expansion of Medicare Reimbursement …” on October 10, 2016, also Globenewswire.com with their article: “Alliqua BioMedical, Inc. Announces Preliminary Second Quarter of Fiscal Year …” published on July 07, 2016, Globenewswire.com published: “Alliqua BioMedical, Inc. Announces Closing of Celleration, Inc. Acquisition” on June 01, 2015. More interesting news about Alliqua Biomedical Inc (NASDAQ:ALQA) were released by: Globenewswire.com and their article: “Alliqua BioMedical, Inc. to Acquire Celleration, Inc.” published on February 02, 2015 as well as Globenewswire.com‘s news article titled: “Alliqua BioMedical, Inc. Appoints Nino Pionati as Chief Strategy and Marketing …” with publication date: June 03, 2015.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.